Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01095913 · ClinicalTrials.gov registry record · Phase 1
Fluorescent Dyes for Lymph Node Mapping
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01095913: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01095913 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01095913, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find lymph nodes before surgery using a dye called indocyanine green (IC-Green). Objectives: 1. To determine the feasibility of using nonradioactive optical imaging techniques with indocyanine green (ICG) as a fluorescent contrast agent to identify all axillary lymph nodes. 2. To determine the feasibility of using nonradioactive optical imaging techniques with ICG as a fluorescent contrast agent to characterize lymphatic architecture and function in women with breast cancer who are scheduled for axillary node dissection.
Interventions
- DRUG Indocyanine green (ICG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01095913
The ClinicalTrials.gov registry entry for NCT01095913 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Indocyanine green (ICG) is the first listed.
NCT01095913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01095913 about?
NCT01095913 is a clinical study titled "Fluorescent Dyes for Lymph Node Mapping". The goal of this clinical research study is to find lymph nodes before surgery using a dye called indocyanine green (IC-Green). Objectives: 1. To determine the feasibility of using nonradioactive optical imaging techniques with indocyanine green (ICG) as a fluorescent contrast agent to identify al...
What is the current status of trial NCT01095913?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-03. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01095913?
The interventions under investigation include: Indocyanine green (ICG) (DRUG).
Who is sponsoring clinical trial NCT01095913?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.